Solving the problem of γ-retroviral vectors containing long terminal repeats

Molecular Therapy

Volumn 19, Issue 2, 2011, Pages 229-231

  Persons, Derek A ^a   Baum, Christopher ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; BETA GLOBIN; GAMMA RETROVIRUS VECTOR; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; WISKOTT ALDRICH SYNDROME PROTEIN;

BETA THALASSEMIA; CD34+ T LYMPHOCYTE; GENE ACTIVATION; GENE EXPRESSION; GENE INSERTION; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; LONG TERMINAL REPEAT; MUTAGENESIS; NOTE; T LYMPHOCYTE; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; RETROVIRIDAE; TERMINAL REPEAT SEQUENCES; TRANSPLANTATION, AUTOLOGOUS; WISKOTT-ALDRICH SYNDROME;

EID: 79551651644     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.305     Document Type: Note

References (17)

1. Boztug, K, Schmidt, M, Schwarzer, A, Banerjee, PP, Diez, IA, Dewey, FA et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 363: 1918-1927.
2. Informationsdienst Wissenschaft. Effective gene therapy for children with Wiskott-Aldrich-syndrome. Press release (11 November 2010).
3. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
4. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
5. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
6. Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204.
7. Aiuti, A and Roncarolo, MG. (2009). Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program 2009: 682-689.
8. Aiuti, A, Cassani, B, Andolfi, G, Mirolo, M, Biasco, L, Recchia, A et al. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117: 2233-2240.
9. Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
10. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
11. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975.
12. Zychlinski, D, Schambach, A, Modlich, U, Maetzig, T, Meyer, J, Grassman, E et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 16: 718-725.
13. Thornhill, SI, Schambach, A, Howe, SJ, Ulaganathan, M, Grassman, E, Williams, D et al. (2008). Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodefi- ciency. Mol Ther 16: 590-598.
14. Throm, RE, Ouma, AA, Zhou, S, Chandrasekaran, A, Lockey, T, Greene, M et al. (2009). Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113: 5104-5110.
15. Straathof, KC, Pulè, MA, Yotnda, P, Dotti, G, Vanin, EF, Brenner, MK et al. (2005). An inducible caspase 9 safety switch for T-cell therapy. Blood 105: 4247-4254.
16. Hoyos, V, Savoldo, B, Quintarelli, C, Mahendravada, A, Zhang, M, Vera, J et al. (2010). Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/ leukemia effects and safety. Leukemia 24: 1160-1170.
17. Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467: 318-322.